Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Egalet: Innovating Abuse Deterrent Drugs

Published 04/03/2016, 05:04 AM
Updated 07/09/2023, 06:31 AM

In late December, Egalet Corporationn (NASDAQ:EGLT) submitted an NDA for its Arymo ER abuse-deterrent (AD) morphine tablet – a widely prescribed opiate with few AD competitors. Management expects to complete clinical trials in early 2017 to support a mid 2017 NDA filing for its AD oxycodone tablet. If approved, this will open Egalet to the $2.5bn market for oxycontin with a proprietary AD formulation.

Advancing development pipeline

Egalet is a specialty pharmaceutical company focused on pain and other conditions where it can use its abuse-deterrent technology to add value to generic drugs. Egalet submitted an NDA for its Arymo ER (Egalet-001) AD morphine tablet in December with and has been assigned a 14 October 2016 PDUFA date. The company is in late-stage trials for its oxycodone tablet (Egalet-002) and expects clinical readouts of intranasal (H216) and oral (H117) human abuse potential studies to support an NDA in mid-2017.

To read the entire report Please click on the pdf File Below

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.